G

This metabolic change occurs at menopause, and almost no one talks to women about it

After menopause, the liver stores more fat, and the risk of hepatic steatosis approaches that of men.

A subtle shift that is rarely addressed in consultations. Women are often prepared for hot flashes, sleep disturbances, and sometimes bone health issues. However, they seldom receive guidance on what is happening with their liver. The menopausal period leads to significant and lasting changes in the way the body stores fat, and the liver is notably affected. Here’s what the data reveals.

The Impact of Decreased Estrogen Levels

Estrogens play a role beyond reproduction; they are crucial for fat distribution in the body and how cells respond to insulin. When estrogen levels drop, two processes unfold simultaneously.

First, there is a redistribution of adipose tissue: fat tends to accumulate around organs rather than beneath the skin. Secondly, insulin resistance gradually sets in, resulting in decreased efficiency of insulin in transporting sugar into cells. These mechanisms together encourage fat accumulation in the liver.

This phenomenon is described in medical literature as metabolic dysfunction-associated steatotic liver disease (MASLD).

A Gender Gap That Is Closing

Data from the French CONSTANCES cohort, reported by health insurance, provides a clear picture of the situation. Among the population studied, 16.7% exhibited metabolic hepatic steatosis, showing a significant gender disparity: 24.6% of men versus 10.1% of women.

This gap, however, diminishes after menopause, as female prevalence aligns with or even surpasses that of men. In other words, the relative protection women once enjoyed disappears with the decline in estrogen. Globally, this condition is estimated to affect 25% of the population, making it the most common chronic liver disease.

The Timing of Menopause Matters

Research involving 89,474 women tracked over five years, presented at European endocrinology conferences, examined the relationship between the age at which menopause occurs and liver health. These findings need further validation.

Women who experience menopause before the age of 50, and especially those before 45, are more likely to develop hepatic steatosis and associated metabolic disorders within the year following menopause. The authors advocate for a simple recommendation: the age of menopause should be factored into the cardiometabolic risk assessment for women, which is not currently standard practice.

A Disease That Provides No Warning Signals

The most concerning aspect is the absence of symptoms. Hepatic steatosis often progresses without any noticeable signs for years. No pain, no specific fatigue—nothing prompts individuals to seek consultation.

When eventually detected, it may have escalated to inflammation or fibrosis of the liver tissue. Fortunately, early stages are largely reversible. The challenge lies in timely identification.

Screening Is Available and Simple

This is the most valuable takeaway from the article: a straightforward screening score called FIB-4 can be calculated from three components: age, transaminases, and platelet count. This involves nothing more than a standard blood test, which is covered by insurance and can be ordered by your physician during a routine check-up.

Medical societies recommend regular non-invasive screenings for individuals with certain risk factors.

SituationRecommendations
Type 2 diabetesSystematic search for steatosis
Elevated transaminases without identified causeLiver investigation
Established metabolic syndromeNon-invasive screening using a score
Early menopause before 45 yearsTo be reported to your doctor

This approach takes up a single line on a prescription. Yet, it is often overlooked, and no one spontaneously suggests this to women entering menopause.

What This Does Not Reflect About Your Body

A significant clarification, as this topic is frequently misunderstood. This transition is hormonal, not behavioral. It affects women of all body types, including those who are thin, and it is not a result of personal choices. The redistribution of fat during menopause is not a sign of giving up; it is simply a mechanical effect of diminished estrogen levels.

It is also important to explicitly state what cannot be observed externally. A liver overloaded with fat is not visibly detectable, and waist circumference does not serve as a diagnosis. The answer lies in a blood test, rather than in visual assessments of your figure. This distinction is critical: it helps prevent transforming useful medical information into another reason for self-judgment.

What You Can Control and What Your Doctor Manages

On your end, the most impactful action is to discuss this in your next consultation, mentioning your age of menopause.

The rest is up to your healthcare provider. Management is individualized, taking into account your overall metabolic status, and it is not limited to a particular diet or singular advice. Be cautious of restrictive dietary protocols touted as solutions; research emphasizes the importance of physical activity and maintaining muscle mass, and no restrictive approach has demonstrated definitive superiority—some may even cause more harm than good.

Sources:

  • French Health Insurance (ameli.fr), “Definition and causes of metabolic hepatic steatosis: MASLD and MASH,” updated on August 28, 2025. Prevalence data from the CONSTANCES cohort (France, 2019). https://www.ameli.fr/assure/sante/themes/steatose-hepatique/definition-facteurs-risque
  • High Authority of Health, “Non-invasive methods of measuring liver fibrosis.”
  • French Association for the Study of the Liver (AFEF), recommendations for the diagnosis and non-invasive monitoring of chronic liver diseases.
  • Research presented at the European Endocrinology Congress on the link between menopause age and hepatic steatosis, involving a cohort of 89,474 women.
  • “Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD,” Liver International, April 2026, DOI 10.1111/liv.70562.